quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:01:24·37d
PRRelease
Oric Pharmaceuticals Inc. logo

ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

ORIC· Oric Pharmaceuticals Inc.
Health Care
Original source

Companies

  • ORIC
    Oric Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Jan 7UpdatePiper Sandler$22.00
  • Nov 20UpdateEvercore ISI$25.00
  • Nov 18UpdateWolfe Research-
  • Sep 4UpdateGuggenheim$18.00
  • Jul 8UpdateLadenburg Thalmann$15.00
  • Oct 31UpdateWells Fargo$20.00

Related

  • PR6d
    ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
  • PR20d
    ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
  • PR23d
    ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
  • PR28d
    ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC
  • PR48d
    ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
  • INSIDER56d
    Chief Financial Officer Piscitelli Dominic exercised 52,000 shares at a strike of $4.36 and sold $702,686 worth of shares (52,000 units at $13.51) (SEC Form 4)
  • SEC58d
    SEC Form 144 filed by Oric Pharmaceuticals Inc.
  • SEC59d
    SEC Form 8-K filed by Oric Pharmaceuticals Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022